[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100440111":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":45,"centralContacts":49,"locations":55,"responsibleParty":75,"collaborators":10,"id":77,"slug":10,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":10,"eligibilityCriteria":81,"healthyVolunteers":78,"sex":82,"minAge":83,"maxAge":10,"enrollmentInfo":84,"targetDuration":10,"studyType":87,"phases":10,"briefSummary":88,"conditions":89,"keywords":10,"overallStatus":58,"whyStopped":10,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational (neurocognitive assessment, questionnaires, MRI)",null,"Patients undergo neurocognitive function assessments, complete questionnaires over 8-10 minutes and undergo standard of care MRI at baseline (within 4 weeks before the first day of WBRT), 2, 6, 12 months after RT completion, then annually for 5 years.",[13,14,15,16],"Procedure: Magnetic Resonance Imaging","Other: Neurocognitive Assessment","Other: Quality-of-Life Assessment","Other: Questionnaire Administration",[18,32,36,42],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"PROCEDURE","Magnetic Resonance Imaging","Undergo MRI",[9],[24,25,26,27,28,29,30,31],"Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance \u002F Nuclear Magnetic Resonance","MR Imaging","MRI","MRI Scan","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging",{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":10},"Neurocognitive Assessment","Undergo neurocognitive function assessment",[9],{"type":6,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Quality-of-Life Assessment","Complete questionnaires",[9],[41],"Quality of Life Assessment",{"type":6,"name":43,"description":38,"armGroupLabels":44,"otherNames":10},"Questionnaire Administration",[9],[46],{"name":47,"affiliation":5,"role":48},"Bouthaina S Dabaja","PRINCIPAL_INVESTIGATOR",[50],{"name":51,"role":52,"phone":53,"phoneExt":10,"email":54},"Dustin M Silk","CONTACT","713-563-3090","dmdmsilk@mdanderson.orgsilk@mdanderson.org",[56],{"facility":57,"status":58,"city":59,"state":60,"zip":61,"country":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"M D Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States",{"type":64,"coordinates":65},"Point",[66,67],-95.36327,29.76328,{"lat":67,"lon":66},[70,73],{"name":71,"role":52,"phone":53,"phoneExt":10,"email":72},"Dustin M. Silk","dmsilk@mdanderson.org",{"name":74,"role":48,"phone":10,"phoneExt":10,"email":10},"Bouthaina S. Dabaja",{"type":76,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100440111",false,"NCT05011045","Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies","Inclusion Criteria:\n\n* Age 18 years or older\n* Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \\[PCNSL\\], secondary central nervous system lymphoma \\[SCNSL\\], leukemia, myeloma)\n* Proficient and capable of completing tests in English\n* Patients with claustrophobia are eligible if the claustrophobia is managed with medication\n* Patients with cognitively-impairment are eligible if the impairment is managed with medication\n* Patients who are pregnant","ALL","18 Years",{"count":85,"type":86},100,"ESTIMATED","OBSERVATIONAL","This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer.",[90,91,92,93,94,95],"Central Nervous System Lymphoma","Hematopoietic and Lymphoid Cell Neoplasm","Leukemia","Lymphoma","Plasma Cell Myeloma","Secondary Central Nervous System Lymphoma","2026-05-18",{"date":98,"type":99},"2026-05-20","ACTUAL",{"date":101,"type":99},"2020-01-09",{"date":103,"type":86},"2026-10-31",{"name":5,"class":6},1]